T1	Treatment 10 22	enzalutamide
T2	Treatment 281 293	Enzalutamide
T3	Treatment 392 399	placebo
T4	Treatment 570 582	enzalutamide
T5	Treatment 782 805	enzalutamide 160 mg/day
T6	Treatment 814 824	or placebo
T7	Treatment 1655 1671	the enzalutamide
T8	Treatment 1706 1720	in the placebo
T9	Treatment 1834 1876	61 with enzalutamide compared with placebo
T10	Treatment 2012 2044	11·1-13·9) in the enzalutamide
T11	Treatment 2067 2081	(5·5-5·6) in
T12	Treatment 2198 2213	patients in the
T13	Treatment 2227 2237	group than
T14	Treatment 2584 2597	CI 5·6-5·7)
T15	Treatment 2633 2651	months (5·4-5·6)
T16	Treatment 2773 2785	enzalutamide
T17	Treatment 2953 2965	(32%) of 872
T18	Treatment 3009 3017	(37%) of
T19	Treatment 3130 3146	skeletal-related
T20	Treatment 3241 3258	(95% CI 23·9-not
T21	Treatment 3363 3389	improving overall survival
